Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
复制标题
DOI：
10.1002/wjo2.15
复制
发表时间：
2022-09
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
PD-1和PD-L1抑制剂已成为头颈部鳞状细胞癌（HNSCC）患者的有希望的治疗方法。HNSCC中PD-1和PD-L1抑制剂的系统综述和Meta分析。成果：中位总生存期（mOS）、中位无进展生存期（mPFS）、实体瘤疗效评价标准（RECIST）和治疗相关不良事件（TRAE）。11项试验报告了1088例患者的数据（平均年龄：59.9岁，范围：18-90岁）。总mOS为7.97个月（范围：6.0-16.5）。所有研究的平均mPFS为2.84个月（范围：1.9-6.5）。PD-1抑制剂的RECIST疾病进展率低于PD-L1抑制剂（42.61%，95%置信区间[CI]：36.29-49.06 vs. 56.79%，95% CI：49.18-64.19，P < 0.001）。任何级别的TRAE发生率（62.7%，95% CI：59.8-65.6）均无差异。Meta分析显示PD-1和PD-L1抑制剂在HNSCC中的疗效，并提示PD-1和PD-L1抑制剂之间的某些RECIST标准可能存在差异。未来的工作，以调查这些发现的临床意义是必要的。PD-1和PD-L1抑制剂已成为头颈部鳞状细胞癌（HNSCC）患者的有希望的治疗方法。我们回顾了11项试验，报告了1，088例患者的数据（平均年龄59.9岁，范围18 - 90）。我们的Meta分析描述了PD-1和PD-L1抑制剂在HNSCC中的疗效，并表明PD-1和PD-L1抑制剂之间在某些RECIST标准上可能存在差异。 本研究的重要结果：在PD-1和PD-L1抑制剂用于头颈部鳞状细胞癌的Meta分析中分析了11项研究。数据显示，与PD-L1抑制剂相比，PD-1抑制剂的RECIST疾病进展率显著降低。 这项研究补充说：我们的Meta分析描述了PD-1和PD-L1抑制剂在HNSCC中的疗效，并表明PD-1和PD-L1抑制剂之间的某些RECIST标准可能存在差异。这为今后指导临床治疗HNSCC奠定了基础。
PD‐1 and PD‐L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC). Systematic review and meta‐analysis of PD‐1 and PD‐L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression‐free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment‐related adverse events (TRAEs). Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18–90). The total mOS was 7.97 months (range: 6.0–16.5). Mean mPFS for all studies was 2.84 months (range: 1.9–6.5). PD‐1 inhibitors had a lower rate of RECIST Progressive Disease than PD‐L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29–49.06 vs. 56.79%, 95% CI: 49.18–64.19, P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8–65.6) did not differ. Meta‐analysis shows the efficacy of PD‐1 and PD‐L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD‐1 and PD‐L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted. PD‐1 and PD‐L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC). We reviewed 11 trials which reported data on 1,088 patients (mean age 59.9 years, range 18‐90). Our meta‐analysis describes the efficacy of PD‐1 and PD‐L1 inhibitors in HNSCC, and suggests a possible difference in certain RECIST criterion between PD‐1 and PD‐L1 inhibitors. Significant Findings of this Study: 11 studies were analyzed in this meta‐analysis of PD‐1 and PD‐L1 inhibitor use in head and neck squamous cell carcinoma. Data showed that PD‐1 inhibitors had a significantly lower rate of RECIST progressive disease when compared to PD‐L1 inhibitors. What this study adds: Our meta‐analysis describes the efficacy of PD‐1 and PD‐L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD‐1 and PD‐L1 inhibitors. This lays foundation for future work to guide clinical treatment of HNSCC.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
PD-1检查点途径的分子和生化方面。
DOI：
10.1056/nejmra1514296
发表时间：
2016-11-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Boussiotis VA
通讯作者：
Boussiotis VA
影响因子：
5.8
作者：
Gillison, Maura L.;Blumenschein, George;Ferris, Robert L.
通讯作者：
Ferris, Robert L.
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS
影响因子：
254.7
作者：
Epstein, Joel B.;Thariat, Juliette;Maghami, Ellie
通讯作者：
Maghami, Ellie